TNFi in auto-immune disorders

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on TNFi in auto-immune disorders
Tumor necrosis factor inhibitors (TNFi) are a class of biologic medications widely used to treat autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn's disease. TNF is a pro-inflammatory cytokine that plays a central role in the inflammatory response characteristic of these conditions. By blocking TNF activity, TNFi medications reduce inflammation, alleviate symptoms, and slow disease progression.
TNFi therapies, such as infliximab, etanercept, and adalimumab, have demonstrated significant clinical benefits, improving the quality of life for many patients. These medications are often prescribed when conventional therapies, like DMARDs, are insufficient. While generally well-tolerated, TNFi can increase the risk of infections, including tuberculosis, due to their immunosuppressive effects. Careful patient monitoring and screening for latent infections are crucial during treatment. Despite potential risks, TNFi therapies have revolutionized the management of autoimmune disorders, offering hope for long-term disease control.
Therefore, get an overall knowledge of TNFi in auto-immune disorders
 

See More Webinars @ Hidoc Webinars